Items Tagged ‘TAS-102’

October 23rd, 2014

Novel Agent Granted Fast Track Designation for Refractory Metastatic Colorectal Cancer

By

The U.S. Food and Drug Administration (FDA) has granted Fast Track designation to TAS-102, a novel agent currently under investigation for the treatment of refractory metastatic colorectal cancer. According to estimates from the American Cancer Society, more than 102,000 new cases of colon cancer and about 40,000 new cases of rectal cancer were diagnosed in […]

View full entry

Tags: Colon Cancer, colorectal cancer, News, Rectal Cancer, refractory colorectal cancer, Stage IV (D)/Relapsed Colon Cancer, Stage IV Rectal Cancer, TAS-102


July 9th, 2014

TAS-102 Improves Survival in Advanced Colorectal Cancer

By

Researchers recently reported that the new combination agent TAS-102 improves overall survival in patients whose metastatic colorectal cancer is refractory to standard therapies. These results were recently reported at the ESMO 16th World Congress on Gastrointestinal Cancer in Barcelona.1 According to estimates from the American Cancer Society, more than 102,000 new cases of colon cancer and about […]

View full entry

Tags: Colon Cancer, colorectal cancer, crc, News, Rectal Cancer, Recurrent/Relapsed Rectal Cancer, Stage IV (D)/Relapsed Colon Cancer, Stage IV Rectal Cancer, TAS-102